68Ga-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients.

Journal Article (Journal Article;Review)

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa.

Full Text

Duke Authors

Cited Authors

  • Sanli, Y; Sanli, O; Has Simsek, D; Subramaniam, RM

Published Date

  • October 2018

Published In

Volume / Issue

  • 39 / 10

Start / End Page

  • 871 - 880

PubMed ID

  • 30124601

Electronic International Standard Serial Number (EISSN)

  • 1473-5628

Digital Object Identifier (DOI)

  • 10.1097/MNM.0000000000000888


  • eng

Conference Location

  • England